WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Thomas Detry's late birdie assured him of a topElizabeth Hurley, 58, displays her incredible figure in a white bikini on holidayChinese youngsters embrace more diversified tourism optionsALISON BOSHOFF: Liz Taylor's shocking claim from beyond the grave...Brest secures final automatic Champions League spot in French league, PSG wins without MbappéTrump hush money trial: What we've learned so far and what to watch for as it wraps upEthiopian PM inaugurates ChinaBarcelona seals lucrative 2nd place in Spain, Sorloth scores 4 as Villarreal draws with Real MadridChina sanctions Boeing, two U.S. defense contractors for Taiwan arms salesMan City stars and their WAGs hit the tiles in style after historic Premier League title win
3.7222s , 6500.90625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Cosmic Coverage news portal